Kodiak Sciences Inc. announced top-line, one-year (48 weeks) results for its ABC Platform based investigational therapy tarcocimab tedromer 5 mg from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion (RVO). Macular edema due to retinal veins occlusion affects approximately 16.4 million adults worldwide and 1.1 million in the United States. Standard of care therapeutic agents are approved for monthly injections.

BEACON is a randomized, double-masked, multicenter, active comparator-controlled Phase 3 clinical trial in treatment naive patients with vision loss and macular edema due to Retinal vein occlusion, including both branch (BRVO) and central (CRVO) subtypes. BEACON randomized 568 participants 1:1 into two treatment arms: tarcocimabtedromer 5 mg versus aflibercept 2mg. The BEACON study results demonstrated: These forward-looking statements are not based on historical fact and include statements regarding: the potential implications of the Beacon results, including their importance and clinical relevance, the possibility that they provide additional supportive evidence for the development of Kodiak's ABC Platform and platform-derived medicines, and additional insights that may be provided by the GLOW data combined with the BEACON results; tarcocimab's differentiated durability profile; the potential for Kodiak's ABC Platform and tarcocimab to be important innovations for patients; the expected timing for completion and release of topline data for the GLOW study; and expectations and plans for the development of KSI-501.

These risks and uncertainties include, but are not limited to: the risk that the BEACON and/or GLOW results may not provide the evidence, insights or benefits as anticipated; the risk that excessation, modification or delay of any of the ongoing clinical studies and development of tarcocimab and/or KSI-501 may occur; the risk that safety, efficacy and durability data observed in product candidates in current or prior studies may not continue or persist; the risk that KSI-501 may not inhibit VEGF and IL-6 or have an impact on the treatment of patients as expected; the risk that any one or more of the product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general study study study.